GARFIELD-VTE
Taking a real-world deep dive into VTE

ABOUT VTE
Venous thromboembolism (VTE) is the formation of blood clots in the vein.

- Pulmonary embolism (PE) is a clot in the lungs
- Deep vein thrombosis (DVT) is a clot in a deep vein (usually in the leg)

3rd
Most common cardiovascular illness, after acute coronary syndrome and stroke.1

37
VTE kills one person every 37 seconds in the Western world.2

2x
In Europe, the annual death rate from VTE is more than twice that of AIDS, breast cancer, prostate cancer and traffic accidents combined per year.3

90%
FATAL CASES OF VTE THAT ARE UNDETECTED OR UNTREATABLE PRIOR TO DEATH.4

780K
Deaths in Europe and the US each year.2

£640M
The amount the UK NHS spends per year on VTE treatment and management.5

Another serious long-term VTE complication is post-thrombotic syndrome (PTS):
- PTS is the most common complication (20 – 50% within 2 years of first DVT) and is severe in 10 – 15% of cases
- PTS costs billions of pounds per year in time lost from work and in medical expenses and leads to disability and reduced quality of life.

ABOUT THE REGISTRY

Study start:
July 2014

Recruitment closed:
September 2016

Study end:
April 2020

The Breakdown:

2 sequential cohorts

28 countries

415 sites

10,879 newly diagnosed VTE patients

Emerging Registry Insights:

Death is the No. 1 major adverse outcome in VTE patients – 50% are cancer-related.

Anticoagulant treatment patterns for VTE vary by patient population, region and DVT site.

Most VTE patients with cancer are treated with LMWH* (as per guidelines), while DOACs* are prescribed to 25% of patients.

VTE patients vary widely and need personalised therapy.

References

For more information, visit www.garfieldregistry.org

The GARFIELD-VTE registry is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).